Sepsis is still the leading cause of death in surgical and general intensive care units. Although our knowledge of this complex syndrome has increased in recent years, it is still far from com plete. New therapeutic approaches have been developed. Some did not fullfill the high expectations for their use in clinical prac tice; others are still under clinical evaluation. is the aim of this monograph to offer basic information on the It etiology, definition, pathophysiology, prevention and therapy of sepsis and septic shock to both the clinician and the scientist. We believe that it presents an…mehr
Sepsis is still the leading cause of death in surgical and general intensive care units. Although our knowledge of this complex syndrome has increased in recent years, it is still far from com plete. New therapeutic approaches have been developed. Some did not fullfill the high expectations for their use in clinical prac tice; others are still under clinical evaluation. is the aim of this monograph to offer basic information on the It etiology, definition, pathophysiology, prevention and therapy of sepsis and septic shock to both the clinician and the scientist. We believe that it presents an extensive overview that may help the clinician to better understand and treat sepsis and septic shock. We also hope that this work will give some directions for future research both in the clinical field as well as the laboratory. Jena, Berlin, Jerusalem, K.Reinhart February 1994 K.Eyrich C.Sprung TableofContents I.Definition/Prognosis Sepsis and Septic Shock: Update on Definitions (Jo-L.Vincent) 0 0 0 0 0 0 0 0 0 0 0 0 3 Clinical Manifestations and Prognostic Indicators in Sepsis (R.C.Bone) ... 0 16 What Determines Prognosis in Sepsis? Evidence for a Comprehensive Individual Patient Risk Assessment Approach to the Design and Analysis of Clinical Trials (W.A.Knaus, D.P.Wagner, F.E.Harrell, Jr.
Produktdetails
Produktdetails
Update in Intensive Care and Emergency Medicine .18
I. Definition/Prognosis.- Sepsis and Septic Shock: Update on Definitions.- Clinical Manifestations and Prognostic Indicators in Sepsis.- What Determines Prognosis in Sepsis? Evidence for a Comprehensive Individual Patient Risk Assessment Approach to the Design and Analysis of Clinical Trials.- A Scoring System for Multiple Organ Dysfunction Syndrome.- II. Pathogenesis.- Endotoxemia and Sepsis: Important Roles for Lipopolysaccharide Binding Protein and CD14 in Endotoxin Signal Transduction.- Bacterial Exotoxins and Sepsis.- Bacterial Translocation: Myth versus Reality.- Tumor Necrosis Factor and Other Cytokines in Septic Syndrome.- Role of Oxygen Free Radicals in the Pathophysiology of Sepsis.- III. Pathophysiology.- Cardiocirculation in Sepsis.- A Current View of Oxygen Supply Dependency.- Sepsis and Nutritional Blood Flow.- Endothelial Cell Function in the Critically Ill.- Sepsis and Cellular Metabolism.- IV. Monitoring.- Monitoring of O2 Transport and Tissue Oxygenation in Septic Shock.- V. Therapy.- Sepsis-Related Problems in Pediatric Patients.- Definitions and Therapy of Sepsis.- Role of Surgical Intervention in the Prevention and Therapy of Sepsis.- Antibacterial Treatment of Sepsis.- Diagnostic and Therapeutic Approach in Invasive Fungal Infections of Intensive Care Unit Patients.- Fluid Therapy in Sepsis.- Influence of Catecholamines on Regional Perfusion and Tissue Oxygenation in Septic Shock Patients.- Metabolic Changes in Sepsis - Can the Host Response be Influenced Metabolically?.- VI. New Therapeutic Approaches.- Is there a Place for Monoclonal Antibodies Against Endotoxin in the Therapy of Sepsis?.- Endotoxin in Septic Shock.- Tumour Necrosis Factor as a Therapeutic Target in Sepsis.- Tumor Necrosis Factor-Neutralization with a Specific MonoclonalAntibody.- Cardiovascular Effects of Repeated Administration of the F(ab')2 Fragment of an Anti-tumor Necrosis Factor-? Monoclonal Antibody in Patients with Severe Sepsis.- Modulating Effects of Pentoxifylline on Cytokine Release Syndromes.- The Treatment of Sepsis with Interleukin-1 Receptor Antagonist.- The Function and Potential Therapeutic Value of Lipopolysaccharide Binding Protein During Gram- Negative Sepsis: Recombinant Expression and Promoter Studies.- Platelet-Activating Factor: Pathophysiological Changes and Therapeutic Implications in Sepsis.- Potential of Oxyradical Scavengers in the Therapy of Sepsis.- N-Acetylcysteine in Sepsis.- Immunoaugmentation: A Contribution to Prophylaxis and Treatment of Sepsis?.- What Is Certain in the Treatment with Immunoglobulins?.- Arachidonic Acid Metabolism in Sepsis: What is the Role of Cyclooxygenase Inhibition?.- Improvement of Monocyte Function A New Therapeutic Approach?.- From Localized Angioedema to Generalized Capillary Leak Syndrome.- Potential for Gene Therapy in the Treatment of Sepsis.- VII. Specific Therapeutic Aspects.- Step-by-Step Treatment of Acute Respiratory Distress Syndrome.- Perfluorocarbons as an Alternative Respiratory Medium.
I. Definition/Prognosis.- Sepsis and Septic Shock: Update on Definitions.- Clinical Manifestations and Prognostic Indicators in Sepsis.- What Determines Prognosis in Sepsis? Evidence for a Comprehensive Individual Patient Risk Assessment Approach to the Design and Analysis of Clinical Trials.- A Scoring System for Multiple Organ Dysfunction Syndrome.- II. Pathogenesis.- Endotoxemia and Sepsis: Important Roles for Lipopolysaccharide Binding Protein and CD14 in Endotoxin Signal Transduction.- Bacterial Exotoxins and Sepsis.- Bacterial Translocation: Myth versus Reality.- Tumor Necrosis Factor and Other Cytokines in Septic Syndrome.- Role of Oxygen Free Radicals in the Pathophysiology of Sepsis.- III. Pathophysiology.- Cardiocirculation in Sepsis.- A Current View of Oxygen Supply Dependency.- Sepsis and Nutritional Blood Flow.- Endothelial Cell Function in the Critically Ill.- Sepsis and Cellular Metabolism.- IV. Monitoring.- Monitoring of O2 Transport and Tissue Oxygenation in Septic Shock.- V. Therapy.- Sepsis-Related Problems in Pediatric Patients.- Definitions and Therapy of Sepsis.- Role of Surgical Intervention in the Prevention and Therapy of Sepsis.- Antibacterial Treatment of Sepsis.- Diagnostic and Therapeutic Approach in Invasive Fungal Infections of Intensive Care Unit Patients.- Fluid Therapy in Sepsis.- Influence of Catecholamines on Regional Perfusion and Tissue Oxygenation in Septic Shock Patients.- Metabolic Changes in Sepsis - Can the Host Response be Influenced Metabolically?.- VI. New Therapeutic Approaches.- Is there a Place for Monoclonal Antibodies Against Endotoxin in the Therapy of Sepsis?.- Endotoxin in Septic Shock.- Tumour Necrosis Factor as a Therapeutic Target in Sepsis.- Tumor Necrosis Factor-Neutralization with a Specific MonoclonalAntibody.- Cardiovascular Effects of Repeated Administration of the F(ab')2 Fragment of an Anti-tumor Necrosis Factor-? Monoclonal Antibody in Patients with Severe Sepsis.- Modulating Effects of Pentoxifylline on Cytokine Release Syndromes.- The Treatment of Sepsis with Interleukin-1 Receptor Antagonist.- The Function and Potential Therapeutic Value of Lipopolysaccharide Binding Protein During Gram- Negative Sepsis: Recombinant Expression and Promoter Studies.- Platelet-Activating Factor: Pathophysiological Changes and Therapeutic Implications in Sepsis.- Potential of Oxyradical Scavengers in the Therapy of Sepsis.- N-Acetylcysteine in Sepsis.- Immunoaugmentation: A Contribution to Prophylaxis and Treatment of Sepsis?.- What Is Certain in the Treatment with Immunoglobulins?.- Arachidonic Acid Metabolism in Sepsis: What is the Role of Cyclooxygenase Inhibition?.- Improvement of Monocyte Function A New Therapeutic Approach?.- From Localized Angioedema to Generalized Capillary Leak Syndrome.- Potential for Gene Therapy in the Treatment of Sepsis.- VII. Specific Therapeutic Aspects.- Step-by-Step Treatment of Acute Respiratory Distress Syndrome.- Perfluorocarbons as an Alternative Respiratory Medium.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826
